Azurity Drug Patent Portfolio
Azurity owns 23 orange book drugs protected by 103 US patents with Thyquidity having the least patent protection, holding only 1 patent. And Katerzia with maximum patent protection, holding 11 patents. Given below is the list of Azurity's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844784 | Stable pharmaceutical compositions of bendamustine | 29 Jul, 2042 | Active |
| US11433046 | Compositions and methods for treating epilepsy, seizures and other conditions | 21 Aug, 2040 | Active |
| US11633374 | Compositions and methods for treating epilepsy, seizures and other conditions | 21 Aug, 2040 | Active |
| US11826343 | Compositions and methods for treating epilepsy, seizures and other conditions | 21 Aug, 2040 | Active |
| US11911362 | Compositions and methods for treating epilepsy, seizures and other conditions | 21 Aug, 2040 | Active |
| US11771686 | Compositions and kits for omeprazole suspension | 01 Mar, 2040 | Active |
| US11931455 | Pharmaceutical suspension for oral dosage | 16 Aug, 2039 | Active |
| US12097284 | Mycophenolate oral suspension | 16 Aug, 2039 | Active |
| US12097285 | Mycophenolate oral suspension | 16 Aug, 2039 | Active |
| US10751333 | Compositions and kits for omeprazole suspension | 16 Jul, 2039 | Active |
| US11103492 | Compositions and kits for omeprazole suspension | 16 Jul, 2039 | Active |
| US11633478 | Compositions and kits for Omeprazole suspension | 16 Jul, 2039 | Active |
| US11911473 | Compositions and kits for omeprazole suspension | 16 Jul, 2039 | Active |
| US12042539 | Compositions and kits for Omeprazole suspension | 16 Jul, 2039 | Active |
| US10799453 | Amlodipine formulations | 11 Apr, 2039 | Active |
| US11311554 | Pharmaceutical compositions of testosterone | 25 Mar, 2039 | Active |
| US11642355 | Pharmaceutical compositions of testosterone | 25 Mar, 2039 | Active |
| US10456354 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | 25 Oct, 2038 | Active |
| US11110054 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | 25 Oct, 2038 | Active |
| US11938217 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | 25 Oct, 2038 | Active |
| US11478456 | Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof | 18 Aug, 2038 | Active |
| US11529333 | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof | 18 Aug, 2038 | Active |
| US10342787 | Non-aqueous liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US10576070 | Non-aqueous liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US11207306 | Non-aqueous liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US11413277 | Non-aqueous liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US11517563 | Liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US11759457 | Liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US11806338 | Non-aqueous liquid nimodipine compositions | 16 Apr, 2038 | Active |
| US10695329 | Amlodipine formulations | 16 Oct, 2037 | Active |
| US10894039 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US10952998 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US10959991 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11364230 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11471409 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11484498 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11701326 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11918685 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US12053461 | Amlodipine formulations | 06 Oct, 2037 | Active |
| US11324696 | Suspensions and diluents for metronidazole and baclofen | 29 Sep, 2037 | Active |
| US11446246 | Suspensions and diluents for metronidazole and baclofen | 08 Sep, 2037 | Active |
| US10441554 | Oral amphetamine composition | 10 Mar, 2037 | Active |
| US11160772 | Oral amphetamine composition | 10 Mar, 2037 | Active |
| US11896562 | Oral amphetamine composition | 10 Mar, 2037 | Active |
| US10039745 | Enalapril formulations | 25 Mar, 2036 | Active |
| US10154987 | Enalapril formulations | 25 Mar, 2036 | Active |
| US10772868 | Enalapril formulations | 25 Mar, 2036 | Active |
| US10786482 | Enalapril formulations | 25 Mar, 2036 | Active |
| US11040023 | Enalapril formulations | 25 Mar, 2036 | Active |
| US11141405 | Enalapril formulations | 25 Mar, 2036 | Active |
| US11173141 | Enalapril formulations | 25 Mar, 2036 | Active |
| US9669008 | Enalapril formulations | 25 Mar, 2036 | Active |
| US9808442 | Enalapril formulations | 25 Mar, 2036 | Active |
| US10039800 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US10265370 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US10406199 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US10940177 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US11179434 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US11771733 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US9463183 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US9616096 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US9814751 | Lisinopril formulations | 06 Nov, 2035 | Active |
| US9724297 | Sotalol compositions and uses of the same | 31 Aug, 2035 | Active |
| US10493028 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US10688046 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US10959946 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US10959947 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US10959948 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US10959949 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US11638692 | Composition and method for vancomycin oral liquid | 13 Mar, 2035 | Active |
| US11850222 | Sotalol compositions and uses of the same | 19 Nov, 2034 | Active |
| US10206895 | Sotalol compositions and uses of the same | 01 Apr, 2034 | Active |
| US11013703 | Sotalol compositions and uses of the same | 01 Apr, 2034 | Active |
| US10231927 | Methotrexate composition | 02 Jan, 2033 | Active |
| US10610485 | Methotrexate composition | 02 Jan, 2033 | Active |
| US11116724 | Methotrexate composition | 02 Jan, 2033 | Active |
| US11969503 | Methotrexate composition | 02 Jan, 2033 | Active |
| US9259427 | Methotrexate composition | 02 Jan, 2033 | Active |
| US9855215 | Methotrexate composition | 02 Jan, 2033 | Active |
| US8568747 | Enalapril compositions | 06 Nov, 2032 | Active |
| US8778366 | Enalapril compositions | 06 Nov, 2032 | Active |
| US9855214 | Enalapril compositions | 06 Nov, 2032 | Active |
| US9968553 | Enalapril compositions | 06 Nov, 2032 | Active |
| US9050307 | Method for the preparation of a levothyroxine solution | 06 Aug, 2031 | Active |
| US9387249 | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone | 01 Jul, 2031 | Active |
| US9169238 | Solid pharmaceutical composition | 04 Feb, 2030 | Active |
| US10166181 | Slow release pharmaceutical composition made of microgranules | 30 Jun, 2029 | Active |
| US8795725 | GABA analog prodrug sustained release oral dosage forms | 10 Jun, 2029 | Active |
| US9066936 | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent | 26 Mar, 2028 | Active |
| US8026279 | Crystalline form of γ-aminobutyric acid analog | 10 Nov, 2026 | Active |
| US8114909 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | 11 Apr, 2026 | Active |
| US7157584 | Benzimidazole derivative and use thereof | 22 May, 2025 | Active |
| US6818787 | Prodrugs of GABA analogs, compositions and uses thereof | 06 Apr, 2025 | Active |
| US8686034 | Crystalline form of γ-aminobutyric acid analog | 24 Jan, 2025 | Active |
| US7572920 | Benzimidazole derivative and use as a II receptor antagonist | 07 Jan, 2025 | Active |
| US8517997 | Dispenser for medicaments and method and apparatus for making same | 14 May, 2024 | Expired |
| US10130580 | Taste-masked pharmaceutical compositions | 19 Apr, 2024 | Expired |
| US7070581 | Dispenser for medicaments and method and apparatus for making same | 23 Jun, 2023 | Expired |
| US8048917 | Prodrugs of GABA analogs, compositions and uses thereof | 06 Nov, 2022 | Expired |
| US6465463 | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate | 08 Sep, 2020 | Expired |
| US6784177 | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate | 08 Sep, 2020 | Expired |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases | 06 Jun, 2014 | Expired |
| US5583141 | Heterocyclic compounds and their use as angiotensin antagonists | 10 Dec, 2013 | Expired |
Latest Legal Activities on Azurity's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Azurity.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Apr, 2024 | US10799453 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9463183 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Mar, 2024 | US10786482 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 26 Mar, 2024 | US11938217 |
| Mail Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
| Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
|
Recordation of Patent Grant Mailed
Critical
| 26 Mar, 2024 | US11938217 |
|
Email Notification
Critical
| 26 Mar, 2024 | US11938217 |
| Recordation of Patent eGrant | 26 Mar, 2024 | US11938217 |
|
Email Notification
Critical
| 07 Mar, 2024 | US11938217 |
|
Issue Notification Mailed
Critical
| 06 Mar, 2024 | US11938217 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11918685 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11918685 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918685 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918685 |
Azurity's Drug Patent Litigations
Azurity's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 10, 2017, against patent number US9463183. The petitioner KVK-Tech, Inc., challenged the validity of this patent, with Silvergate Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Azurity's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9463183 | July, 2017 |
FWD Entered
(07 May, 2018)
| Silvergate Pharmaceuticals, Inc. | KVK-Tech, Inc. |
Azurity Drug Patents' Oppositions Filed in EPO
Azurity drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 04, 2008, by Breuer, Markus. This opposition was filed on patent number EP02744314A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12172232A | Apr, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP08763237A | Sep, 2017 | Ferring B.V. | Revoked |
| EP08763237A | Sep, 2017 | Generics (UK) Ltd | Revoked |
| EP11711688A | Jul, 2016 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Granted and Under Opposition |
| EP02744314A | Sep, 2008 | Breuer, Markus | Patent maintained as amended |
Azurity's Family Patents
Azurity Drug List
Given below is the complete list of Azurity's drugs and the patents protecting them.
1. Azmiro
Azmiro is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11311554 | Pharmaceutical compositions of testosterone |
25 Mar, 2039
(14 years from now)
| Active |
| US11642355 | Pharmaceutical compositions of testosterone |
25 Mar, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azmiro's drug page
2. Bidil
Bidil is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6465463 | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
08 Sep, 2020
(4 years ago)
| Expired |
| US6784177 | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
08 Sep, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bidil's drug page
3. Edarbi
Edarbi is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9066936 | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
26 Mar, 2028
(3 years from now)
| Active |
| US7157584 | Benzimidazole derivative and use thereof |
22 May, 2025
(5 months from now)
| Active |
| US7572920 | Benzimidazole derivative and use as a II receptor antagonist |
07 Jan, 2025
(a month from now)
| Active |
| US5958961 | Pharmaceutical composition for angiotensin II-mediated diseases |
06 Jun, 2014
(10 years ago)
| Expired |
| US5583141 | Heterocyclic compounds and their use as angiotensin antagonists |
10 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbi's drug page
4. Edarbyclor
Edarbyclor is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9387249 | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
01 Jul, 2031
(6 years from now)
| Active |
| US9169238 | Solid pharmaceutical composition |
04 Feb, 2030
(5 years from now)
| Active |
| US9066936 | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
26 Mar, 2028
(3 years from now)
| Active |
| US7157584 | Benzimidazole derivative and use thereof |
22 May, 2025
(5 months from now)
| Active |
| US7572920 | Benzimidazole derivative and use as a II receptor antagonist |
07 Jan, 2025
(a month from now)
| Active |
| US5583141 | Heterocyclic compounds and their use as angiotensin antagonists |
10 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbyclor's drug page
5. Epaned
Epaned is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039745 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US10154987 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US10772868 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US10786482 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US11040023 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US11141405 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US11173141 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US9669008 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
| US9808442 | Enalapril formulations |
25 Mar, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned's drug page
Explore Our Curated Drug Screens
6. Epaned Kit
Epaned Kit is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8568747 | Enalapril compositions |
06 Nov, 2032
(7 years from now)
| Active |
| US8778366 | Enalapril compositions |
06 Nov, 2032
(7 years from now)
| Active |
| US9855214 | Enalapril compositions |
06 Nov, 2032
(7 years from now)
| Active |
| US9968553 | Enalapril compositions |
06 Nov, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned Kit's drug page
7. Eprontia
Eprontia is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11433046 | Compositions and methods for treating epilepsy, seizures and other conditions |
21 Aug, 2040
(15 years from now)
| Active |
| US11633374 | Compositions and methods for treating epilepsy, seizures and other conditions |
21 Aug, 2040
(15 years from now)
| Active |
| US11826343 | Compositions and methods for treating epilepsy, seizures and other conditions |
21 Aug, 2040
(15 years from now)
| Active |
| US11911362 | Compositions and methods for treating epilepsy, seizures and other conditions |
21 Aug, 2040
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eprontia's drug page
8. Evekeo Odt
Evekeo Odt is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10441554 | Oral amphetamine composition |
10 Mar, 2037
(12 years from now)
| Active |
| US11160772 | Oral amphetamine composition |
10 Mar, 2037
(12 years from now)
| Active |
| US11896562 | Oral amphetamine composition |
10 Mar, 2037
(12 years from now)
| Active |
| US10130580 | Taste-masked pharmaceutical compositions |
19 Apr, 2024
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evekeo Odt's drug page
9. Firvanq Kit
Firvanq Kit is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10493028 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US10688046 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US10959946 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US10959947 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US10959948 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US10959949 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
| US11638692 | Composition and method for vancomycin oral liquid |
13 Mar, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firvanq Kit's drug page
10. Fleqsuvy
Fleqsuvy is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11324696 | Suspensions and diluents for metronidazole and baclofen |
29 Sep, 2037
(12 years from now)
| Active |
| US11446246 | Suspensions and diluents for metronidazole and baclofen |
08 Sep, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fleqsuvy's drug page
11. Horizant
Horizant is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8795725 | GABA analog prodrug sustained release oral dosage forms |
10 Jun, 2029
(4 years from now)
| Active |
| US8026279 | Crystalline form of γ-aminobutyric acid analog |
10 Nov, 2026
(1 year, 11 months from now)
| Active |
| US8114909 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
11 Apr, 2026
(1 year, 4 months from now)
| Active |
| US6818787 | Prodrugs of GABA analogs, compositions and uses thereof |
06 Apr, 2025
(4 months from now)
| Active |
| US8686034 | Crystalline form of γ-aminobutyric acid analog |
24 Jan, 2025
(a month from now)
| Active |
| US8048917 | Prodrugs of GABA analogs, compositions and uses thereof |
06 Nov, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Horizant's drug page
12. Katerzia
Katerzia is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10799453 | Amlodipine formulations |
11 Apr, 2039
(14 years from now)
| Active |
| US10695329 | Amlodipine formulations |
16 Oct, 2037
(12 years from now)
| Active |
| US10894039 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US10952998 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US10959991 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US11364230 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US11471409 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US11484498 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US11701326 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US11918685 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
| US12053461 | Amlodipine formulations |
06 Oct, 2037
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Katerzia's drug page
13. Konvomep
Konvomep is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11771686 | Compositions and kits for omeprazole suspension |
01 Mar, 2040
(15 years from now)
| Active |
| US10751333 | Compositions and kits for omeprazole suspension |
16 Jul, 2039
(14 years from now)
| Active |
| US11103492 | Compositions and kits for omeprazole suspension |
16 Jul, 2039
(14 years from now)
| Active |
| US11633478 | Compositions and kits for Omeprazole suspension |
16 Jul, 2039
(14 years from now)
| Active |
| US11911473 | Compositions and kits for omeprazole suspension |
16 Jul, 2039
(14 years from now)
| Active |
| US12042539 | Compositions and kits for Omeprazole suspension |
16 Jul, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Konvomep's drug page
14. Myhibbin
Myhibbin is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11931455 | Pharmaceutical suspension for oral dosage |
16 Aug, 2039
(14 years from now)
| Active |
| US12097284 | Mycophenolate oral suspension |
16 Aug, 2039
(14 years from now)
| Active |
| US12097285 | Mycophenolate oral suspension |
16 Aug, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myhibbin's drug page
15. Nymalize
Nymalize is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10342787 | Non-aqueous liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US10576070 | Non-aqueous liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US11207306 | Non-aqueous liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US11413277 | Non-aqueous liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US11517563 | Liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US11759457 | Liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US11806338 | Non-aqueous liquid nimodipine compositions |
16 Apr, 2038
(13 years from now)
| Active |
| US8517997 | Dispenser for medicaments and method and apparatus for making same |
14 May, 2024
(6 months ago)
| Expired |
| US7070581 | Dispenser for medicaments and method and apparatus for making same |
23 Jun, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nymalize's drug page
16. Prevduo
Prevduo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10456354 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
25 Oct, 2038
(13 years from now)
| Active |
| US11110054 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
25 Oct, 2038
(13 years from now)
| Active |
| US11938217 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
25 Oct, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevduo's drug page
17. Qbrelis
Qbrelis is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039800 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US10265370 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US10406199 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US10940177 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US11179434 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US11771733 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US9463183 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US9616096 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
| US9814751 | Lisinopril formulations |
06 Nov, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qbrelis's drug page
18. Sotylize
Sotylize is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9724297 | Sotalol compositions and uses of the same |
31 Aug, 2035
(10 years from now)
| Active |
| US11850222 | Sotalol compositions and uses of the same |
19 Nov, 2034
(9 years from now)
| Active |
| US10206895 | Sotalol compositions and uses of the same |
01 Apr, 2034
(9 years from now)
| Active |
| US11013703 | Sotalol compositions and uses of the same |
01 Apr, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sotylize's drug page
19. Thyquidity
Thyquidity is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9050307 | Method for the preparation of a levothyroxine solution |
06 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thyquidity's drug page
20. Triptodur Kit
Triptodur Kit is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166181 | Slow release pharmaceutical composition made of microgranules |
30 Jun, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triptodur Kit's drug page
21. Vivimusta
Vivimusta is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11844784 | Stable pharmaceutical compositions of bendamustine |
29 Jul, 2042
(17 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivimusta's drug page
22. Xatmep
Xatmep is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10231927 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
| US10610485 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
| US11116724 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
| US11969503 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
| US9259427 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
| US9855215 | Methotrexate composition |
02 Jan, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xatmep's drug page
23. Zonisade
Zonisade is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11478456 | Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof |
18 Aug, 2038
(13 years from now)
| Active |
| US11529333 | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
18 Aug, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zonisade's drug page